TNFRSF10A and type 1 diabetes mellitus: In this regard, HLA class II alleles may influence individual responses to immunomodulatory therapies, as evidenced by studies showing that the presence of DR4 were associated with better treatment responses when the anti-CD3 monoclonal antibody, teplizumab, was used to delay the clinical onset of type 1 diabetes (30).